Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASINO: Anti-TNF vs Surgery for Crohn's Ileitis
NCT02872506Withdrawn
- Sponsor
- CHU de Lille
- Start
- Sep 2017
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
01
Overview
Open-label trial of infliximab in Crohn's disease (2 arms), sponsored by CHU de Lille. Primary endpoint: Quality of Life by Inflammatory Bowel Disease Questionnaire at 6 months. Planned start Sep 2017; status: withdrawn.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02872506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02872506.